{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:18:55Z","timestamp":1790486335154,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s00280-015-2788-6","type":"journal-article","created":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T16:54:10Z","timestamp":1435683250000},"page":"489-498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma"],"prefix":"10.1007","volume":"76","author":[{"given":"David","family":"Fogelman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Sugar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Alewine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huamin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Javle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachna","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Abbruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Laheru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Luis A.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,1]]},"reference":[{"key":"2788_CR1","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris III","year":"1997","unstructured":"Burris HA III, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403\u20132413","journal-title":"J Clin Oncol"},{"key":"2788_CR2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New Engl J Med 364:1817\u20131825","journal-title":"New Engl J Med"},{"key":"2788_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Hoff Von","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New Engl J Med 369:1691\u20131703","journal-title":"New Engl J Med"},{"key":"2788_CR4","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960\u20131966","journal-title":"J Clin Oncol"},{"issue":"2","key":"2788_CR5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00280-011-1704-y","volume":"69","author":"A De Jesus-Acosta","year":"2012","unstructured":"De Jesus-Acosta A, Oliver GR, Blackford A, Kinsman K, Flores EI, Wilfong LS, Zheng L, Donehower RC, Cosgrove D, Laheru D, Le DT, Chung K, Diaz LA Jr (2012) A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol 69(2):415\u2013424. doi: 10.1007\/s00280-011-1704-y","journal-title":"Cancer Chemother Pharmacol"},{"key":"2788_CR6","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1200\/JCO.2008.19.9067","volume":"27","author":"M Kriege","year":"2009","unstructured":"Kriege M, Seynaeve C, Meijers-Heijboer H et al (2009) Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27:3764\u20133771","journal-title":"J Clin Oncol"},{"key":"2788_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. New Engl J Med 361:123\u2013134","journal-title":"New Engl J Med"},{"key":"2788_CR8","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nm852","volume":"9","author":"T Taniguchi","year":"2003","unstructured":"Taniguchi T, Tischkowitz M, Ameziane N et al (2003) Disruption of the Fanconi anemia\u2013BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9:568\u2013574","journal-title":"Nat Med"},{"key":"2788_CR9","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1097\/CAD.0b013e32832b511e","volume":"20","author":"E James","year":"2009","unstructured":"James E, Waldron-Lynch MG, Saif MW (2009) Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs 20:634\u2013638","journal-title":"Anticancer Drugs"},{"key":"2788_CR10","first-page":"305","volume":"9","author":"P Chalasani","year":"2008","unstructured":"Chalasani P, Kurtin S, Dragovich T (2008) Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation. JOP 9:305\u2013308","journal-title":"JOP"},{"key":"2788_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913\u2013917","journal-title":"Nature"},{"key":"2788_CR12","doi-asserted-by":"publisher","first-page":"7508","DOI":"10.1158\/1078-0432.CCR-05-1048","volume":"11","author":"MS Heijden van der","year":"2005","unstructured":"van der Heijden MS, Brody JR, Dezentje DA et al (2005) In vivo therapeutic responses contingent on Fanconi anemia\/BRCA2 status of the tumor. Clin Cancer Res 11:7508\u20137515","journal-title":"Clin Cancer Res"},{"key":"2788_CR13","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1053\/j.gastro.2009.06.055","volume":"137","author":"MD Tischkowitz","year":"2009","unstructured":"Tischkowitz MD, Sabbaghian N, Hamel N et al (2009) Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology 137:1183\u20131186","journal-title":"Gastroenterology"},{"key":"2788_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00439-008-0554-0","volume":"124","author":"W Al-Sukhni","year":"2008","unstructured":"Al-Sukhni W, Rothenmund H, Borgida AE et al (2008) Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Hum Genet 124:271\u2013278","journal-title":"Hum Genet"},{"key":"2788_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/ng1959","volume":"39","author":"N Rahman","year":"2007","unstructured":"Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165\u2013167","journal-title":"Nat Genet"},{"key":"2788_CR16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/0008-5472.383.65.2","volume":"65","author":"FJ Couch","year":"2005","unstructured":"Couch FJ, Johnson MR, Rabe K et al (2005) Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 65:383\u2013386","journal-title":"Cancer Res"},{"key":"2788_CR17","first-page":"2585","volume":"63","author":"MS Heijden van der","year":"2003","unstructured":"van der Heijden MS, Yeo CJ, Hruban RH, Kern SE (2003) Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 63:2585\u20132588","journal-title":"Cancer Res"},{"key":"2788_CR18","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/1055-9965.EPI-06-0783","volume":"16","author":"FJ Couch","year":"2007","unstructured":"Couch FJ, Johnson MR, Rabe KG et al (2007) The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomark Prev 16:342\u2013346","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2788_CR19","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1200\/JCO.20.6.1480","volume":"20","author":"TS Frank","year":"2002","unstructured":"Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20:1480\u20131490","journal-title":"J Clin Oncol"},{"key":"2788_CR20","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","volume":"91","author":"Breast Cancer Linkage C","year":"1999","unstructured":"Breast Cancer Linkage C (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310\u20131316","journal-title":"J Natl Cancer Inst"},{"key":"2788_CR21","first-page":"5360","volume":"56","author":"M Goggins","year":"1996","unstructured":"Goggins M, Schutte M, Lu J et al (1996) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56:5360\u20135364","journal-title":"Cancer Res"},{"key":"2788_CR22","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1126\/science.1073834","volume":"297","author":"NG Howlett","year":"2002","unstructured":"Howlett NG, Taniguchi T, Olson S et al (2002) Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606\u2013609","journal-title":"Science"},{"key":"2788_CR23","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/bjc.2014.418","volume":"111","author":"T Golan","year":"2014","unstructured":"Golan T, Kanji ZS, Epelbaum R et al (2014) Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111:1132\u20131138","journal-title":"Br J Cancer"},{"key":"2788_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4161\/cbt.12.3.16292","volume":"12","author":"A Sonnenblick","year":"2011","unstructured":"Sonnenblick A, Kadouri L, Appelbaum L et al (2011) Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol Ther 12:165\u2013168","journal-title":"Cancer Biol Ther"},{"key":"2788_CR25","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1002\/cncr.11310","volume":"97","author":"I Cass","year":"2003","unstructured":"Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY (2003) Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97:2187\u20132195","journal-title":"Cancer"},{"key":"2788_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jama.2012.20","volume":"307","author":"KL Bolton","year":"2012","unstructured":"Bolton KL, Chenevix-Trench G, Goh C et al (2012) Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307:382\u2013390","journal-title":"JAMA"},{"key":"2788_CR27","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C et al (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30:2654\u20132663","journal-title":"J Clin Oncol"},{"key":"2788_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1200\/JCO.2008.20.7019","volume":"28","author":"T Byrski","year":"2010","unstructured":"Byrski T, Gronwald J, Huzarski T et al (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375\u2013379","journal-title":"J Clin Oncol"},{"key":"2788_CR29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10549-014-3100-x","volume":"147","author":"T Byrski","year":"2014","unstructured":"Byrski T, Huzarski T, Dent R et al (2014) Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 147:401\u2013405","journal-title":"Breast Cancer Res Treat"},{"key":"2788_CR30","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-09-2758","volume":"16","author":"A Mukhopadhyay","year":"2010","unstructured":"Mukhopadhyay A, Elattar A, Cerbinskaite A et al (2010) Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res 16:2344\u20132351","journal-title":"Clin Cancer Res"},{"key":"2788_CR31","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1023\/A:1026595525977","volume":"11","author":"V Heinemann","year":"2000","unstructured":"Heinemann V, Wilke H, Mergenthaler HG et al (2000) Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 11:1399\u20131403","journal-title":"Ann Oncol"},{"key":"2788_CR32","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","volume":"23","author":"C Louvet","year":"2005","unstructured":"Louvet C, Labianca R, Hammel P et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509\u20133516","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2788-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2788-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2788-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2788-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T22:12:49Z","timestamp":1691791969000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2788-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,1]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["2788"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2788-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,1]]},"assertion":[{"value":"17 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}